Published in PLoS Pathog on September 18, 2009
Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog (2012) 1.74
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (2011) 1.55
Cell-to-Cell Spread of Retroviruses. Viruses (2010) 1.27
Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin. J Biol Chem (2012) 1.18
Imaging single retrovirus entry through alternative receptor isoforms and intermediates of virus-endosome fusion. PLoS Pathog (2011) 1.08
HIV entry: a game of hide-and-fuse? Curr Opin Virol (2013) 1.04
A quantitative and kinetic fusion protein-triggering assay can discern distinct steps in the nipah virus membrane fusion cascade. J Virol (2010) 1.01
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol (2011) 0.94
CD4-independent human immunodeficiency virus infection involves participation of endocytosis and cathepsin B. PLoS One (2011) 0.93
Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides. Eur Biophys J (2011) 0.93
Visualization of retrovirus uptake and delivery into acidic endosomes. Biochem J (2011) 0.92
Intercellular adhesion molecule 1 promotes HIV-1 attachment but not fusion to target cells. PLoS One (2012) 0.88
Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41. FASEB J (2011) 0.86
Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion. PLoS One (2011) 0.86
Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother (2012) 0.86
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses (2012) 0.86
Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. PLoS Pathog (2016) 0.82
SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins. J Biol Chem (2017) 0.81
Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors. J Biol Chem (2017) 0.81
Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics. Retrovirology (2014) 0.80
Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum. PLoS Pathog (2013) 0.80
Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection. Biomaterials (2013) 0.79
Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms. J Virol (2014) 0.79
A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion. PLoS One (2013) 0.78
Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency. Biophys J (2011) 0.77
The β-Lactamase Assay: Harnessing a FRET Biosensor to Analyse Viral Fusion Mechanisms. Sensors (Basel) (2016) 0.77
Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. PLoS Pathog (2016) 0.77
Visualization of Content Release from Cell Surface-Attached Single HIV-1 Particles Carrying an Extra-Viral Fluorescent pH-Sensor. PLoS One (2016) 0.76
Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion. PLoS Comput Biol (2014) 0.75
Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors. Assay Drug Dev Technol (2017) 0.75
Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure. PLoS One (2013) 0.75
Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. PLoS Pathog (2017) 0.75
Dynamin-2 Stabilizes the HIV-1 Fusion Pore with a Low Oligomeric State. Cell Rep (2017) 0.75
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science (1998) 12.52
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
HIV entry and its inhibition. Cell (1998) 9.42
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem (2001) 8.96
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature (1988) 6.28
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol (2000) 5.71
Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol (1998) 5.62
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol (2002) 5.49
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med (1998) 4.77
HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell (2009) 4.63
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A (1998) 4.34
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol (1998) 3.60
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol (1997) 3.04
Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol (2000) 2.95
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A (2003) 2.92
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol (2006) 2.57
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A (2004) 2.44
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog (2009) 2.34
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 2.31
HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell (2003) 2.18
HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry (2001) 2.07
Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J Virol (2001) 2.06
The role of CD4 in HIV binding and entry. Philos Trans R Soc Lond B Biol Sci (1993) 1.99
Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol (2003) 1.95
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. J Virol (1994) 1.92
Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol (2002) 1.79
Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol (2005) 1.73
Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J Virol (2003) 1.72
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol (2004) 1.69
Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol (1999) 1.68
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol (2005) 1.65
Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol (2002) 1.64
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol (2005) 1.53
A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors. Proc Natl Acad Sci U S A (2000) 1.45
Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol (2003) 1.30
Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry (2005) 1.20
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry (2007) 1.13
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol (2004) 1.10
Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci (2008) 1.01
Functional impact of HIV coreceptor-binding site mutations. Virology (2006) 1.00
Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. J Med Chem (2005) 0.99
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology (2006) 0.98
How proteins produce cellular membrane curvature. Nat Rev Mol Cell Biol (2006) 6.90
Mechanics of membrane fusion. Nat Struct Mol Biol (2008) 4.79
Protein-lipid interplay in fusion and fission of biological membranes. Annu Rev Biochem (2003) 4.77
HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell (2009) 4.63
How synaptotagmin promotes membrane fusion. Science (2007) 4.46
Membrane proteins of the endoplasmic reticulum induce high-curvature tubules. Science (2008) 3.60
Stalk model of membrane fusion: solution of energy crisis. Biophys J (2002) 3.51
Mechanisms determining the morphology of the peripheral ER. Cell (2010) 3.35
Membrane fission is promoted by insertion of amphipathic helices and is restricted by crescent BAR domains. Cell (2012) 3.26
The hydrophobic insertion mechanism of membrane curvature generation by proteins. Biophys J (2008) 2.98
Mechanisms shaping the membranes of cellular organelles. Annu Rev Cell Dev Biol (2009) 2.71
Membrane hemifusion: crossing a chasm in two leaps. Cell (2005) 2.61
Focal adhesions as mechanosensors: a physical mechanism. Proc Natl Acad Sci U S A (2005) 2.43
Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog (2010) 2.33
Membrane curvature in synaptic vesicle fusion and beyond. Cell (2010) 2.09
Membranes of the world unite! J Cell Biol (2006) 2.06
Assembly and mechanosensory function of focal adhesions: experiments and models. Eur J Cell Biol (2005) 2.06
Lipid intermediates in membrane fusion: formation, structure, and decay of hemifusion diaphragm. Biophys J (2002) 2.00
Stacked endoplasmic reticulum sheets are connected by helicoidal membrane motifs. Cell (2013) 1.97
Membrane fission: model for intermediate structures. Biophys J (2003) 1.84
Computational model of membrane fission catalyzed by ESCRT-III. PLoS Comput Biol (2009) 1.78
Spontaneous curvature of phosphatidic acid and lysophosphatidic acid. Biochemistry (2005) 1.66
Interplay of proteins and lipids in generating membrane curvature. Curr Opin Cell Biol (2010) 1.64
Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion. Retrovirology (2011) 1.49
Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J Virol (2005) 1.42
Stalk phase formation: effects of dehydration and saddle splay modulus. Biophys J (2004) 1.28
Prefission constriction of Golgi tubular carriers driven by local lipid metabolism: a theoretical model. Biophys J (2003) 1.21
Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin. J Biol Chem (2012) 1.18
Role of focal adhesions and mechanical stresses in the formation and progression of the lamellipodium-lamellum interface [corrected]. Biophys J (2009) 1.14
How lipid flippases can modulate membrane structure. Biochim Biophys Acta (2008) 1.13
Extracellular annexins and dynamin are important for sequential steps in myoblast fusion. J Cell Biol (2012) 1.12
Modeling membrane shaping by proteins: focus on EHD2 and N-BAR domains. FEBS Lett (2009) 1.08
Imaging single retrovirus entry through alternative receptor isoforms and intermediates of virus-endosome fusion. PLoS Pathog (2011) 1.08
Computational model of cytokinetic abscission driven by ESCRT-III polymerization and remodeling. Biophys J (2012) 1.04
Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem (2011) 1.04
Physical model for self-organization of actin cytoskeleton and adhesion complexes at the cell front. Biophys J (2012) 1.03
Intracellular curvature-generating proteins in cell-to-cell fusion. Biochem J (2011) 1.02
Fusion of mature HIV-1 particles leads to complete release of a gag-GFP-based content marker and raises the intraviral pH. PLoS One (2013) 1.02
A novel mechanism of actin filament processive capping by formin: solution of the rotation paradox. J Cell Biol (2005) 1.01
Fusion-pore expansion during syncytium formation is restricted by an actin network. J Cell Sci (2008) 0.99
Point-like protrusion as a prestalk intermediate in membrane fusion pathway. Biophys J (2007) 0.98
Influenza hemagglutinins outside of the contact zone are necessary for fusion pore expansion. J Biol Chem (2004) 0.97
Quantitative imaging of endosome acidification and single retrovirus fusion with distinct pools of early endosomes. Proc Natl Acad Sci U S A (2012) 0.95
Synchronized retrovirus fusion in cells expressing alternative receptor isoforms releases the viral core into distinct sub-cellular compartments. PLoS Pathog (2012) 0.94
Visualization of retrovirus uptake and delivery into acidic endosomes. Biochem J (2011) 0.92
Actin polymerization upon processive capping by formin: a model for slowing and acceleration. Biophys J (2006) 0.91
Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother (2007) 0.89
Orientation and interaction of oblique cylindrical inclusions embedded in a lipid monolayer: a theoretical model for viral fusion peptides. Biophys J (2004) 0.89
Anionic lipids are required for vesicular stomatitis virus G protein-mediated single particle fusion with supported lipid bilayers. J Biol Chem (2013) 0.88
Intercellular adhesion molecule 1 promotes HIV-1 attachment but not fusion to target cells. PLoS One (2012) 0.88
Biophysics: Joint effort bends membrane. Nature (2010) 0.87
Biophysics: bending over to attract. Nature (2007) 0.85
Crawling cell locomotion revisited. Proc Natl Acad Sci U S A (2011) 0.81
Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum. PLoS Pathog (2013) 0.80
High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors. Assay Drug Dev Technol (2015) 0.79
Force-driven polymerization in cells: actin filaments and focal adhesions. J Phys Condens Matter (2005) 0.79
Heat evolution of micelle formation, dependence of enthalpy, and heat capacity on the surfactant chain length and head group. J Colloid Interface Sci (2002) 0.78
Model of T-cell nuclear deformation by the cortical actin layer. Biophys J (2013) 0.75
Cell boundary and intracellular space. Preface. Curr Top Membr (2011) 0.75